Single Nucleotide Polymorphism Genotyping Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology (TaqMan SNP Genotyping, Massarray SNP Genotyping, SNP GeneChip Arrays, Others), By Application (Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology, Others), by region, and Competit
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationSingle Nucleotide Polymorphism Genotyping Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology (TaqMan SNP Genotyping, Massarray SNP Genotyping, SNP GeneChip Arrays, Others), By Application (Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology, Others), by region, and Competit
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 8.15 billion |
| CAGR (2024-2028) | 17.20% |
| Fastest Growing Segment | TaqMan SNP Genotyping |
| Largest Market | North America |
Market Overview
Global Single Nucleotide Polymorphism Genotyping Market has valued at USD 8.15 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 17.20% through 2028.
The field of pharmacogenomics uses genetic data, often obtained through SNP genotyping, to optimize drug selection and dosages. This is especially important for medications with a narrow therapeutic index.
Key Market Drivers
Technological Advancements
Next-Generation Sequencing (NGS) technologies, such as Illumina's sequencing platforms, have revolutionized genotyping. NGS allows for the simultaneous genotyping of thousands to millions of SNPs in a single experiment, making it a powerful tool for genome-wide association studies (GWAS) and other applications. DNA microarrays are used to simultaneously genotype thousands of SNPs. They offer a high-throughput and cost-effective approach to genotyping. Microarray-based platforms like Affymetrix and Illumina have gained widespread adoption. Real-time PCR-based assays, like TaqMan and allele-specific PCR, are used for SNP genotyping. These assays offer high specificity, sensitivity, and real-time data acquisition, making them valuable in research and clinical settings.
Digital PCR technology enables absolute quantification of target DNA molecules, including SNP alleles. It is highly precise and can detect rare alleles or variants with high accuracy. Mass spectrometry-based genotyping methods, such as MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization-Time of Flight), are used to analyze SNP alleles. These methods offer high throughput and accuracy. Allele-Specific Oligonucleotide Ligation Assay (ASO-LA) techniques involve hybridizing SNP-specific oligonucleotides with target DNA, followed by ligation of SNP-specific probes. This method is highly specific and can be used in multiplex format. Automation and robotics have enabled high-throughput SNP genotyping. These platforms, like Fluidigm's Biomark and Bio-Rad's BioMark HD, are suitable for large-scale genotyping projects. The use of nanotechnology, such as nanowires and nanoparticles, has been explored to improve the sensitivity and specificity of SNP genotyping assays. The CRISPR-Cas system can be adapted for SNP genotyping by designing guide RNAs that specifically target SNP sites. It allows for precise and multiplexed genotyping.
Advances in data analysis and bioinformatics tools have become crucial. Software for SNP calling, haplotype phasing, and interpretation of genotyping data has improved. The integration of SNP genotyping with single-cell analysis has allowed researchers to explore genetic diversity at the individual cell level, providing insights into clonal evolution and tissue heterogeneity. Efforts are ongoing to develop portable and point-of-care genotyping devices that can rapidly analyze SNP data at the bedside or in resource-limited settings. Advances in sample preparation techniques have reduced the time and cost associated with DNA extraction and purification, making genotyping more efficient. This factor will help in the development of the
Increase Demand in Forensic Science and Ancestry Testing
SNP genotyping is used in forensic DNA analysis to identify individuals, such as in criminal investigations. SNPs are highly polymorphic and can help distinguish one individual from another, even within a close biological relationship. SNPs can be used to analyze evidence collected from crime scenes, such as blood, hair, or other bodily fluids, to determine the genetic profile of a suspect or victim. SNP genotyping technology has been instrumental in solving cold cases by reexamining evidence from unsolved crimes, sometimes years or decades later. In cases where biological relationships need to be confirmed (e.g., paternity, or maternity testing), SNP genotyping can be used to establish family connections with a high degree of accuracy. In forensic anthropology and archaeology, SNP genotyping is used to identify human remains, especially in mass disasters or historical investigations.
Ancestry testing services, like 23andMe and Ancestry.com, utilize SNP genotyping to provide customers with information about their genetic heritage, including ancestral origins, migration patterns, and family tree connections. Consumers are interested in learning more about their heritage and ethnic background. SNP genotyping helps individuals trace their genetic roots and discover their ancestral origins. Ancestry testing relies on large reference databases of SNP data to compare an individual's genetic markers to global populations, allowing for estimates of the person's ancestry. Some ancestry testing services also offer insights into genetic health risks and inherited traits. SNP data is used to provide these personalized genetic reports. This factor will pace up the demand of the
Rise in Drug Development
Identifying appropriate drug targets is a fundamental step in drug development. Single Nucleotide Polymorphism (SNP) genotyping is used to discover genetic variations associated with specific diseases, making it easier to identify potential drug targets. Understanding the genetic basis of a disease allows researchers to develop drugs that target the underlying causes. Drug development often involves clinical trials to test the safety and efficacy of new medications. Single Nucleotide Polymorphism genotyping helps stratify patient populations based on their genetic profiles, ensuring that the right patients are enrolled in clinical trials. This can increase the chances of success and lead to more personalized treatment approaches. Single Nucleotide Polymorphism genotyping is essential for pharmacogenomic studies, which examine how an individual's genetic makeup influences their response to drugs. This knowledge is critical for tailoring drug treatments to individual patients, optimizing dosages, and minimizing adverse reactions. Single Nucleotide Polymorphism genotyping can help predict how certain individuals might react to a drug, including whether they are at risk for adverse events. This information is invaluable in assessing a drug's safety profile. Single Nucleotide Polymorphism genotyping can be used to determine whether certain genetic variants in patients affect the drug's efficacy. This information can guide dosing adjustments and the selection of alternative treatments for non-responders.
Single Nucleotide Polymorphism genotyping is used to discover and validate biomarkers related to drug responses and treatment outcomes. These biomarkers can help streamline drug development and improve the accuracy of clinical trial results. Single Nucleotide Polymorphism genotyping is applied in animal models and preclinical studies to better understand how genetic factors influence drug metabolism, toxicity, and efficacy. In some cases, SNP genotyping is used to develop companion diagnostics that are paired with specific drugs to identify patients who are most likely to benefit from those treatments. This precision medicine approach is increasingly important in drug development. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), increasingly require pharmacogenomic data, including Single Nucleotide Polymorphism genotyping information, in drug submissions. This ensures that genetic factors are considered in drug development and safety assessments. By incorporating Single Nucleotide Polymorphism genotyping data, clinical trial designs can be optimized to maximize the chances of successful drug development, reduce costs, and accelerate the path to market. This factor will accelerate the demand of the Global Single Nucleotide Polymorphism Genotyping Market
Key Market Challenges
Cost and Accessibility
Many SNP genotyping technologies, such as next-generation sequencing (NGS) and microarrays, involve substantial costs for equipment, reagents, and data analysis. This can be a barrier for research institutions, clinical laboratories, and smaller companies with limited budgets. Ongoing costs related to reagents, consumables, and maintenance can be a significant financial burden. The high cost per sample for some genotyping methods may limit their use, especially in large-scale projects. While the cost of genotyping instruments has come down, the complexity of data analysis and the need for high-performance computing infrastructure can still be expensive. Effective bioinformatics support is often required to derive meaningful insights from genotyping data. The genotyping market has seen increased competition, which has driven companies to offer more cost-effective solutions. However, this competition can lead to market saturation, making it challenging for companies to differentiate their products based on cost. In resource-constrained settings, such as low- and middle-income countries, the high cost of genotyping technologies can limit access to advanced genetic testing and research capabilities. Access to SNP genotyping services and technologies can be limited in rural or remote areas, where advanced laboratories and infrastructure may not be found at.
Complexity of Genetic Variations
The human genome is highly diverse, with millions of SNPs and other genetic variants spread across the genome. Understanding how specific SNPs are associated with traits, diseases, or drug responses can be challenging due to this inherent genetic heterogeneity. Rare and novel SNPs, which are not well-represented in reference databases, can be particularly challenging to identify and interpret. These variants may have important clinical implications, but their rarity makes them less accessible for genotyping and research. SNPs in close physical proximity on a chromosome can exhibit linkage disequilibrium, meaning they are inherited together. Interpreting the functional impact of a single SNP may require considering its relationships with neighboring SNPs. Genetic interactions, where the effect of one SNP is dependent on the presence of another SNP, can add complexity to genetic studies. Detecting and characterizing such interactions requires large datasets and sophisticated analytical methods. While SNP genotyping primarily focuses on single-nucleotide changes, structural variations like Copy Number Variations (CNVs) can also influence genetic traits and disease susceptibility. These require specialized genotyping and analysis methods. Many complex traits, including common diseases, are influenced by multiple SNPs and genes, as well as environmental factors. Untangling the contribution of individual SNPs in such contexts is intricate. Understanding the functional significance of SNPs, such as their impact on gene expression or protein function, is an ongoing challenge. Variants in non-coding regions can have important regulatory roles.
Key Market Trends
Agriculture and Biotechnology
SNP genotyping is used to identify specific genetic markers associated with desirable traits in crops, such as disease resistance, yield, and nutritional content. Genomic selection techniques help breeders make informed decisions about which plants to select for further breeding. SNP markers are employed in marker-assisted breeding programs to accelerate the development of new crop varieties with improved characteristics. This approach reduces the time required to develop and release new, high-performing crop varieties. Identifying SNP markers associated with disease resistance allows breeders to develop crop varieties that are more resilient to pests and pathogens, reducing the need for chemical interventions.
Segmental Insights
Technology Insights
In 2022, the Global Single Nucleotide Polymorphism Genotyping Market largest share was held by TaqMan SNP Genotyping segment and is predicted to continue expanding over the coming years.
Application Insights
In 2022, the Global Single Nucleotide Polymorphism Genotyping Market largest share was held by Pharmaceuticals and Pharmacogenomics segment and is predicted to continue expanding over the coming years.
Regional Insights
The North America region dominates the Global Single Nucleotide Polymorphism Genotyping Market in 2022. North America, particularly the United States and Canada, has a strong tradition of scientific research and innovation. Many renowned research institutions, universities, and biotechnology companies are based in this region. These institutions drive SNP genotyping research and technological advancements. North America has a substantial investment in healthcare and biotechnology. Government funding, private investment, and venture capital play significant roles in supporting research and development in genomics and genetics. The region has access to state-of-the-art genotyping technologies and equipment. Leading companies in the genotyping industry, such as Illumina, Thermo Fisher Scientific, and Affymetrix (acquired by Thermo Fisher), are headquartered or have a strong presence in North America. North America is home to a sizable biopharmaceutical industry. SNP genotyping is essential for drug development, pharmacogenomics, and clinical trials. This proximity to pharmaceutical companies drives demand for SNP genotyping services and technologies. Government initiatives and research projects related to genetics, genomics, and personalized medicine contribute to the growth of the SNP genotyping market. The National Institutes of Health (NIH) and various Canadian research agencies fund many genomics projects.
Recent Developments
- In March 2021, thequadricep tendon has been added to the AlloConnex range of tendons, ligaments,and fascia by AlloSource, one of the leading allograft providers in the UnitedStates. AlloSource develops cutting-edge cellular and tissue allografts toassist surgeons in healing their patients. Recently, it has become more commonto repair ligaments using a quadricep tendon. AlloSource's AlloConnex quadriceptendon, which is offered with or without the bone block for different surgicalapproaches, is a reliable solution for cruciate ligament surgeries. A wide range of operations that surgeons carry out are supported by the AlloConnextendon and ligament portfolio. In addition to the novel quadricep tendon, theAlloConnex portfolio of specialised allografts also includes the patellarligaments, Achilles, anterior tibialis, gracilis, peroneus longus, posteriortibialis, and semitendinosus tendons. The tendon supply offered by AlloSourceconsists of single strand, double strand, and pre-shaped variants.
- In February 2021, ThermoFisher Scientific, the global leader in scientific solutions, has unveiled theApplied Biosystems TaqMan SARS-CoV-2 Mutation Panel. This panel offers acustomizable selection of 22 verified real-time PCR assays designed for theidentification of SARS-CoV-2 mutations. These assays empower the monitoring ofvariants responsible for COVID-19 infections in specific regions worldwide andgrant laboratories the flexibility to select the mutations they wish to track.Given the numerous mutations in SARS-CoV-2, some of which may affect theefficacy of treatments and vaccines, ongoing surveillance of viral changes isof paramount importance. The TaqMan SARS-CoV-2 Mutation Panel is highlyadaptable, capable of analysing a small or large number of samples to identifyone or multiple mutations. This versatility allows laboratories to meet varyingtesting requirements using the real-time PCR instruments they already have. Thepanel delivers results in approximately one hour and utilizes the reliableTaqMan SNP genotyping assay technology, ensuring efficient mutation detectionand differentiation.
Key Market Players
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Danaher Corporation
- Douglas Scientific LLC
- Illumina Inc.
- Life Technologies Corp.
- Luminex Corp
- Promega Corporation
- Thermo Fischer Scientific Inc.
- Fluidigm Corporation
| By Technology | By Application | By Region |
|
|
|
Report Scope
In this report, the Global Single Nucleotide Polymorphism Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below
- Single Nucleotide Polymorphism Genotyping Market, By Technology
o
o
o
o
- Single Nucleotide Polymorphism Genotyping Market, By Application
o
o
o
o
o
o
- Single Nucleotide Polymorphism Genotyping Market, By region
o
o
o
o
o
Competitive Landscape
Company Profiles
found at Customizations
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Global Single Nucleotide Polymorphism Genotyping Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy